Effect | None |
Trial Design | Double blind |
Trial Length | 1-6 months |
Number of Subjects | 36 |
Sex | Both Genders |
Age Range | 45-64, 65+ |
Body Types | Obese |
In obese type II diabetic (on medication) subjects given supplemental chromium via yeast (400 micrograms daily) for 12 weeks was associated with a decrease in blood glucose relative to placebo but all other measured biomarkers were unchanged, although a reduction in insulin and weight in both groups tended to decrease further with chromium.
Lipid peroxidation (MDA) was unaffected and the antioxidant enzymes were mostly unaffected, although a decrease in glutathoine and glutathione peroxidase seen at the end of the trial in placebo was mitigated with chromium.